Semaphore Solutions secures new investment to accelerate Labbit’s AI-driven expansion

Semaphore Solutions, a Vancouver-based laboratory informatics provider, has received additional funding from Cypress Ridge Capital to further scale Labbit, the company’s AI-powered lab orchestration platform. Positioned as the only agentic AI lab platform tailored to clinical, molecular diagnostics, biopharmaceutical, and manufacturing QC workflows, Labbit has rapidly expanded its footprint since its initial backing by Cypress Ridge Capital in February 2023. This latest round of growth equity aims to deepen that momentum by accelerating both organic growth and targeted acquisitions.

Labbit distinguishes itself by combining configurable workflow automation based on Business Process Model and Notation (BPMN) with a semantic Resource Description Framework (RDF) graph database, enabling dynamic task orchestration and intelligent data management. As a result, the platform functions as a co-pilot—an “agentic” AI layer—that assists labs in managing compliance, improving reproducibility, and streamlining operational efficiency through adaptive, AI-enhanced data flows.

Why Labbit is becoming the agentic AI platform of choice for modern laboratories

The growing reliance on digital transformation and data-centric workflows in the life sciences and diagnostics industries has created urgent demand for platforms that can not only capture complex data but also intelligently act on it. Labbit addresses this by offering a unified, modular architecture that allows users to define workflows using BPMN, integrate AI agents for SOP execution, and maintain data relationships using graph-based databases.

This configuration supports laboratories’ evolving needs for interoperability and data standardisation in line with FAIR data principles—Findable, Accessible, Interoperable, and Reusable. As the regulatory environment grows increasingly stringent, especially in molecular diagnostics and manufacturing QC sectors, Labbit’s AI-enhanced orchestration helps organisations respond to compliance requirements dynamically rather than through manual interventions.

Since Cypress Ridge Capital’s initial investment, Labbit has been adopted by leading clinical and diagnostics institutions, including Billion to One, Veracyte, and Peter MacCallum Cancer Centre. These organisations have leveraged the platform to reduce workflow complexity, increase diagnostic throughput, and improve data accessibility across their operational pipelines. The agentic AI layer enables these laboratories to move beyond rigid LIMS (Laboratory Information Management Systems) architectures by offering real-time automation and configurable compliance frameworks.

Investment to drive deeper AI integration and expansion into global laboratory markets

With its renewed investment, Cypress Ridge Capital is doubling down on its commitment to Semaphore Solutions and the growing agentic AI laboratory automation market. According to Semaphore Solutions Chief Executive Officer Peter Smith, the partnership has been instrumental in establishing Labbit as a transformative platform in scientific informatics. The latest funding will support continued innovation in generative AI and accelerate the company’s acquisition strategy to expand capabilities and geographic reach.

Labbit’s integration of Camunda for task management and workflow modeling—enhanced by generative AI—allows laboratories to define highly complex procedures without extensive software development. AI agents embedded within the platform not only assist with workflow execution but also adapt over time, learning from data interactions to suggest optimizations and flag compliance risks.

This level of adaptability has proven valuable for companies operating under strict regulatory oversight, particularly in biopharmaceutical manufacturing and clinical diagnostics. In these environments, the ability to iterate workflows in response to new quality standards, production variables, or research findings offers a strategic edge.

As Semaphore Solutions scales, it intends to invest in its commercial infrastructure and customer support systems to serve a wider base of laboratories across North America, Europe, and Asia-Pacific. The company’s growth strategy includes expanding into adjacent verticals, such as cell and gene therapy development, biomanufacturing scale-up, and personalized medicine diagnostics, all of which require robust, dynamic informatics platforms capable of handling multidimensional data relationships.

Agentic AI and semantic lab orchestration reshape digital transformation in life sciences

Industry observers note that agentic AI represents the next major evolution in laboratory informatics. Unlike traditional automation platforms that operate based on pre-coded logic, agentic systems enable AI to function as a collaborative layer—acting semi-autonomously within defined parameters to adjust workflows, flag anomalies, and reduce decision-making bottlenecks. Labbit’s architecture has positioned Semaphore Solutions as an early leader in this space.

Moreover, the integration of RDF graph databases means that Labbit can represent data relationships semantically, rather than relying solely on static schemas. This is particularly useful in genomics, proteomics, and biomanufacturing, where data sets are interconnected and require contextual interpretation. Combined with BPMN-based process orchestration, the platform allows for full lifecycle tracking—from sample intake to final reporting—with real-time visibility into performance and compliance.

Such capabilities are increasingly being sought by global laboratories navigating the dual pressures of regulatory complexity and technological disruption. By offering a single platform that integrates agentic AI, FAIR data principles, and semantic modeling, Labbit is helping laboratories achieve digital maturity faster and more reliably.

Market trends show increasing investor interest in AI-powered life sciences infrastructure

The investment by Cypress Ridge Capital aligns with a broader trend in the life sciences and diagnostics sector: a growing emphasis on platforms that combine AI with deep domain expertise in regulatory and scientific data. While many AI ventures have focused on clinical decision support or drug discovery, Semaphore Solutions has carved out a unique niche by addressing the “last mile” of lab operations—the processes that connect research, diagnostics, compliance, and production.

With the diagnostics and QC informatics market expected to exceed USD 10 billion by the end of the decade, platforms like Labbit are likely to play a critical role in modernising legacy systems. As biopharma companies ramp up production of complex biologics, and diagnostic labs expand testing panels for personalised medicine, the need for agile, AI-integrated systems will continue to grow.

Semaphore Solutions appears well-positioned to capitalise on this shift, particularly given its dual focus on deep technology (through agentic AI and RDF graph models) and vertical applicability across clinical, biopharma, and QC workflows.